CG Oncology (CGON) Preferred Stock Liabilities (2023)
CG Oncology (CGON) reported Preferred Stock Liabilities of $10.0 million for Q4 2023, down 91.67% quarter-over-quarter from $120.0 million in Q3 2023.
CG Oncology (CGON) Preferred Stock Liabilities (2023) Analysis & Trends
CG Oncology has reported Preferred Stock Liabilities for 1 years, with the latest figure at $10.0 million in Q4 2023.
- For the quarter ending Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Dec 2023 stood at $10.0 million (changed N/A YoY), and the FY2023 full-year result was $10.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2023 stood at $10.0 million, down from $120.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $120.0 million in Q2 2023, with the low at $10.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | 120.00 Mn |
| Jun 30, 2023 | 120.00 Mn |
| Mar 31, 2023 | 22.00 Mn |